Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Metastatic hormone-sensitive prostate cancer, drawn from the whole corpus: 22 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Who needs triplet therapy and who is overtreated by it.
Whether intermittent or de-escalated therapy is safe after a deep PSA response.
PSMA PET restages many men the trials called non-metastatic, and the evidence has not caught up.
Nothing recorded yet.
Background: Oligometastatic disease. Also on OnCo: Atlas of advanced disease · How cancer spreads: the metastasis stages.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 25 changes by month →When this page itself was last checked or edited.
PSMA+ metastatic hormone-sensitive prostate cancer with ARPI (PSMAddition)
A milestone in how this cancer is treated.
mHSPC with ADT alone (ARANOTE)
rPFS significantly improved (HR reported at presentation); approved 2026.
rPFS HR 0.